BOB体育

Skip to main content

Sub Subramony, MD : Research

Neuromuscular Medicine Specialist

Additional languages:
Hindi,
Malayalam,
Tamil
Photo of Sub Subramony

Research at a glance

Top areas of exploration

  • Spinocerebellar Ataxias , 31 publications
  • Friedreich Ataxia , 29 publications
  • Phenotype , 19 publications
  • Spinocerebellar Degenerations , 17 publications

Research activity

178 publications

9,337 citations

Why is this important?

Focus

My key research interests include phenotypic characterization, phenotype-genotype correlations and pathogenic mechansims in genetically induced cerebellar ataxias and muscular dystrophies. In addition, I also am interested in developing assessment methods, biomarker discovery and therapeutic modalities for such diseases.

Active clinical trials

END-DM1

Building on previous work of the Myotonic Dystrophy Clinical Research Network (DMCRN), the present study seeks to overcome insufficient data on natural history; lack of reliable biomarkers; and incomplete characterization and limited biological鈥�

Investigator
Sub Subramony
Status
Accepting Candidates
Ages
18 Years - 70 Years
Sexes
All
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

Spinocerebellar ataxias (SCA) are genetic neurological diseases that cause imbalance, poor coordination, and speech difficulties. There are different kinds of SCA and this study will focus on types 1, 2,3, and 6 (SCA 1, SCA 2, SCA 3 , also known as鈥�

Investigators
Matthew R Burns, Sub Subramony
Status
Accepting Candidates
Ages
6 Years - N/A
Sexes
All

My publications

178 publications

2022

Brief assessment of cognitive function in myotonic dystrophy: Multicenter longitudinal study using computer-assisted evaluation.

Muscle & nerve

鈥�

2022

Clinical management guidelines for Friedreich ataxia: best practice in rare diseases.

Orphanet journal of rare diseases

鈥�

2022

Inherited Ataxias in Children.

Pediatric neurology

鈥�

2022

Natural History of Friedreich Ataxia: Heterogeneity of Neurologic Progression and Consequences for Clinical Trial Design.

Neurology

鈥�

2022

Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease.

Neurology

鈥�